We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
5 Stocks with Robust Sales Growth to Overcome Macro Challenges
Markets started 2025 on a positive note but have since faced considerable volatility. Tariff-related headwinds and geopolitical uncertainty persist, yet the Federal Reserve's interest rate cut signals a softening labor market and the inflationary effects of trade policies. The central bank hinted at two more rate cuts before the year's end. Given this macroeconomic backdrop, choosing the correct stocks remains challenging for retail investors.
Therefore, sales growth provides a more dependable lens for evaluating stocks than traditional earnings-focused metrics. Hence, stocks such as Universal Health Services Inc., Methanex Corp.,Arista Networks, Inc., Voya Financial Inc. and Maximus, Inc. are worth considering for investment.
When evaluating a company, sales growth is often given a preference over earnings. Consistent sales growth reflects the actual demand for a company's products or services. Focusing on sales also offers investors greater visibility into the durability of a company's business model. The company that can expand its top line during periods of economic stress signals pricing power, competitive advantages and the ability to capture market share.
On the other hand, earnings can be distorted by one-off charges, cost-cutting, accounting adjustments or temporary margin expansions, making them less indicative of a company's underlying trajectory.
Moreover, sustained sales growth often translates into stronger and more predictable cash flows, providing management with the financial flexibility to reinvest in innovation, expand into new markets or return capital to shareholders, all without excessive reliance on debt. Robust cash reserves and steady cash flow provide companies with the flexibility to weather challenges, pursue growth opportunities and sustain operational stability even in uncertain conditions.
5 Stocks with Attractive Sales Growth to Buy
King of Prussia, PA-based Universal Health Services owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers and radiation oncology centers. UHS operates more than 350 inpatient acute care hospitals and 60 outpatient and other facilities across 39 states, Washington, DC, the United Kingdom and Puerto Rico.
UHS' expected sales growth rate for 2025 is 8.5%. Universal Health Services carries a Zacks Rank #2 at present.
Methanex, headquartered in Vancouver, Canada, is a leading global supplier of methanol. MEOH has production sites in New Zealand, the United States, Trinidad and Tobago, Egypt, Canada and Chile.
Methanex's expected sales growth rate for 2025 is 5.6%. PGR currently sports a Zacks Rank #1.
Headquartered in Santa Clara, CA, Arista provides cloud networking solutions for data centers and cloud computing environments. At the core of ANET's cloud networking solutions is the Linux-based Extensible Operating System.
Arista's sales are expected to jump 25.4% in 2025. ANET carries a Zacks Rank #2 at present.
Based in New York, Voya Financial operates as a retirement, investment and employee benefits company. VOYA offers products and services through financial intermediaries, independent producers, affiliated advisors and dedicated sales specialists.
Voya Financial's expected sales growth for 2025 is 16.1%. VOYA, at present, carries a Zacks Rank #2.
Reston, VA-based Maximus operates government health and human services programs globally. MMS has built a strong reputation as a trusted partner to governments worldwide, delivering cost-effective, scalable solutions in health and human services.
Maximus' sales are expected to grow 2.7% in fiscal 2025. MMS sports a Zacks Rank #1 at present.
Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zacks.com featured highlights include Universal Health Services, Methanex, Arista Networks, Voya Financial and Maximus
For Immediate Release
Chicago, IL – September 22, 2025 – Stocks in this week’s article are Universal Health Services Inc. (UHS - Free Report) , Methanex Corp. (MEOH - Free Report) , Arista Networks, Inc. (ANET - Free Report) , Voya Financial Inc. (VOYA - Free Report) and Maximus, Inc. (MMS - Free Report) .
5 Stocks with Robust Sales Growth to Overcome Macro Challenges
Markets started 2025 on a positive note but have since faced considerable volatility. Tariff-related headwinds and geopolitical uncertainty persist, yet the Federal Reserve's interest rate cut signals a softening labor market and the inflationary effects of trade policies. The central bank hinted at two more rate cuts before the year's end. Given this macroeconomic backdrop, choosing the correct stocks remains challenging for retail investors.
Therefore, sales growth provides a more dependable lens for evaluating stocks than traditional earnings-focused metrics. Hence, stocks such as Universal Health Services Inc., Methanex Corp.,Arista Networks, Inc., Voya Financial Inc. and Maximus, Inc. are worth considering for investment.
When evaluating a company, sales growth is often given a preference over earnings. Consistent sales growth reflects the actual demand for a company's products or services. Focusing on sales also offers investors greater visibility into the durability of a company's business model. The company that can expand its top line during periods of economic stress signals pricing power, competitive advantages and the ability to capture market share.
On the other hand, earnings can be distorted by one-off charges, cost-cutting, accounting adjustments or temporary margin expansions, making them less indicative of a company's underlying trajectory.
Moreover, sustained sales growth often translates into stronger and more predictable cash flows, providing management with the financial flexibility to reinvest in innovation, expand into new markets or return capital to shareholders, all without excessive reliance on debt. Robust cash reserves and steady cash flow provide companies with the flexibility to weather challenges, pursue growth opportunities and sustain operational stability even in uncertain conditions.
5 Stocks with Attractive Sales Growth to Buy
King of Prussia, PA-based Universal Health Services owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers and radiation oncology centers. UHS operates more than 350 inpatient acute care hospitals and 60 outpatient and other facilities across 39 states, Washington, DC, the United Kingdom and Puerto Rico.
UHS' expected sales growth rate for 2025 is 8.5%. Universal Health Services carries a Zacks Rank #2 at present.
Methanex, headquartered in Vancouver, Canada, is a leading global supplier of methanol. MEOH has production sites in New Zealand, the United States, Trinidad and Tobago, Egypt, Canada and Chile.
Methanex's expected sales growth rate for 2025 is 5.6%. PGR currently sports a Zacks Rank #1.
Headquartered in Santa Clara, CA, Arista provides cloud networking solutions for data centers and cloud computing environments. At the core of ANET's cloud networking solutions is the Linux-based Extensible Operating System.
Arista's sales are expected to jump 25.4% in 2025. ANET carries a Zacks Rank #2 at present.
Based in New York, Voya Financial operates as a retirement, investment and employee benefits company. VOYA offers products and services through financial intermediaries, independent producers, affiliated advisors and dedicated sales specialists.
Voya Financial's expected sales growth for 2025 is 16.1%. VOYA, at present, carries a Zacks Rank #2.
Reston, VA-based Maximus operates government health and human services programs globally. MMS has built a strong reputation as a trusted partner to governments worldwide, delivering cost-effective, scalable solutions in health and human services.
Maximus' sales are expected to grow 2.7% in fiscal 2025. MMS sports a Zacks Rank #1 at present.
Get the remaining stock on the list and start putting this and other ideas to the test. It can all be done with the Research Wizard stock picking and backtesting software.
The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.
Click here to sign up for a free trial of the Research Wizard today.
For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/2753854/5-stocks-with-robust-sales-growth-to-overcome-macro-challenges
Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.
About Screen of the Week
Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine. But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.
Strong Stocks that Should Be in the News
Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.
Follow us on Twitter: https://www.twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Contact: Jim Giaquinto
Company: Zacks.com
Phone: 312-265-9268
Email: pr@zacks.com
Visit: https://www.zacks.com/
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.